Warning! GuruFocus detected
3 Medium warning signs
with CTE.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Cryosite Ltd
ISIN : AU000000CTE1
Description
Cryosite Ltd is engaged in the provision of supply chain logistics, and management of pharmaceutical products used in clinical trials. The company's operating segment includes Cord Blood and Tissue Storage and Clinical Trials and Biological Services Logistics. It generates maximum revenue from the Clinical Trials and Biological Services Logistics segment. The clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labeling, status management, secondary packaging, scheduled drug distribution, destruction, returns, and biological services.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.9 | |||||
| Equity-to-Asset | 0.07 | |||||
| Debt-to-Equity | 1.8 | |||||
| Debt-to-EBITDA | 0.77 | |||||
| Interest Coverage | 101.23 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 2.28 | |||||
| Beneish M-Score | -2.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.8 | |||||
| 3-Year EBITDA Growth Rate | 20.2 | |||||
| 3-Year EPS without NRI Growth Rate | 43 | |||||
| 3-Year FCF Growth Rate | 186.4 | |||||
| 3-Year Book Growth Rate | 55.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.47 | |||||
| 9-Day RSI | 34.72 | |||||
| 14-Day RSI | 39.82 | |||||
| 3-1 Month Momentum % | -12.35 | |||||
| 6-1 Month Momentum % | -0.67 | |||||
| 12-1 Month Momentum % | 14.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.78 | |||||
| Quick Ratio | 1.77 | |||||
| Cash Ratio | 1.03 | |||||
| Days Inventory | 5.42 | |||||
| Days Sales Outstanding | 51.41 | |||||
| Days Payable | 87.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.67 | |||||
| Dividend Payout Ratio | 1.89 | |||||
| Forward Dividend Yield % | 11.33 | |||||
| 5-Year Yield-on-Cost % | 2.67 | |||||
| 3-Year Average Share Buyback Ratio | -1.4 | |||||
| Shareholder Yield % | 3.12 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 64.51 | |||||
| Operating Margin % | 17.33 | |||||
| Net Margin % | 14.26 | |||||
| FCF Margin % | 16.37 | |||||
| ROE % | 97.17 | |||||
| ROA % | 9.01 | |||||
| ROIC % | 12.21 | |||||
| 3-Year ROIIC % | -46.37 | |||||
| ROC (Joel Greenblatt) % | 60.8 | |||||
| ROCE % | 13.99 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 20.27 | |||||
| PE Ratio without NRI | 20.27 | |||||
| Shiller PE Ratio | 57.83 | |||||
| Price-to-Owner-Earnings | 16.3 | |||||
| PEG Ratio | 0.45 | |||||
| PS Ratio | 2.85 | |||||
| PB Ratio | 27.78 | |||||
| Price-to-Tangible-Book | 25 | |||||
| Price-to-Free-Cash-Flow | 17.44 | |||||
| Price-to-Operating-Cash-Flow | 13.89 | |||||
| EV-to-EBIT | 15.22 | |||||
| EV-to-EBITDA | 11.22 | |||||
| EV-to-Revenue | 2.68 | |||||
| EV-to-FCF | 16.39 | |||||
| Price-to-GF-Value | 0.99 | |||||
| Price-to-Projected-FCF | 3.41 | |||||
| Price-to-Median-PS-Value | 2.21 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.79 | |||||
| Price-to-Graham-Number | 5 | |||||
| Earnings Yield (Greenblatt) % | 6.57 | |||||
| FCF Yield % | 5.74 | |||||
| Forward Rate of Return (Yacktman) % | 22.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cryosite Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 12.85 | ||
| EPS (TTM) (A$) | 0.037 | ||
| Beta | -0.09 | ||
| 3-Year Sharpe Ratio | 0.53 | ||
| 3-Year Sortino Ratio | 0.78 | ||
| Volatility % | 59.88 | ||
| 14-Day RSI | 39.82 | ||
| 14-Day ATR (A$) | 0.008947 | ||
| 20-Day SMA (A$) | 0.7785 | ||
| 12-1 Month Momentum % | 14.62 | ||
| 52-Week Range (A$) | 0.64 - 1.25 | ||
| Shares Outstanding (Mil) | 48.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cryosite Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cryosite Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cryosite Ltd Frequently Asked Questions
What is Cryosite Ltd(ASX:CTE)'s stock price today?
The current price of ASX:CTE is A$0.75. The 52 week high of ASX:CTE is A$1.25 and 52 week low is A$0.64.
When is next earnings date of Cryosite Ltd(ASX:CTE)?
The next earnings date of Cryosite Ltd(ASX:CTE) is .
Does Cryosite Ltd(ASX:CTE) pay dividends? If so, how much?
The Dividend Yield %  of Cryosite Ltd(ASX:CTE) is 2.67% (As of Today), Highest Dividend Payout Ratio of Cryosite Ltd(ASX:CTE) was 2. The lowest was 0.35. And the median was 1.67. The  Forward Dividend Yield % of Cryosite Ltd(ASX:CTE) is 11.33%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers